Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Kybella

Phase 1Small molecule

Kybella is one of 38 small molecule programs targeting Fibroma. It is currently in Phase 1.

3

Indications

5

Total Trials

3

Active Trials

37

Competitors

Pipeline

Status by Indication[3][1]

Indication

FibromaActive, not recruiting

Neurofibromatosis Type 1Active, not recruiting

LipomaActive, not recruiting

FibromaPhase 1

Active, not recruiting

Neurofibromatosis Type 1Phase 1

Active, not recruiting

LipomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

41 competitors in Neurofibromatosis Type 1

#DrugCompanyPhaseTrials

Ritalin

Afinitor

Verzenio

Temodar

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Acetadote

AArbor Pharmaceuticals, Inc.

Lamictal

GGlaxo Dba Glaxosmithkline

Levulan

BBiomed Industries, Inc.

Celebrex

PPhiladelphia Eye Associates

Koselugo

Cysteine Hydrochloride

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Recruiting

Lipoma

NCT07237425

Clinical

Trials by Indication[1]

Neurofibromatosis Type 12 trials

Tolerability of Device Based Therapies for Neurofibromatosis Type 1 Cutaneous Neurofibromas

Completed·MMassachusetts General Hospital·Phase 1·NCT04730583·34 enrolled

Dosing and Tolerability of Deoxycholic Acid vs. Polidocanol in the Treatment of Neurofibromatosis Type 1 Cutaneous Neurofibromas

Completed·MMassachusetts General Hospital·Phase 1·NCT06120036·20 enrolled

Patient Satisfaction1 trial

A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVÉDERM® Products, KYBELLA, CoolSculpting Elite and SkinMedica Products

Active, not recruiting· AbbVie logo

AbbVie·Phase 4·NCT06783621·130 enrolled

Lipoma1 trial

Intralesional Ronkyla Plus Injection for the Treatment of Superficial Lipoma

Recruiting·GGlonova Pharma Co., Ltd·Phase 1·NCT07237425·56 enrolled

Fibroma1 trial

Assessing the Efficacy of Repeat, Monthly Treatments of Deoxycholate for NF1 Associated Cutaneous Neurofibromas (cNFs)

Enrolling by invitation·MMassachusetts General Hospital·Phase 1·NCT06300502·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Kybella. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Kybella compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Kybella. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AbbVie company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: AbbVie

Related News